المؤلفون: Schmidt-Ott U; Bayer AG, Berlin, Germany., Hughes D; Regeneron Pharmaceuticals, Inc.,Tarrytown, New York., Chu K; Regeneron Pharmaceuticals, Inc.,Tarrytown, New York., Reed K; Regeneron Pharmaceuticals, Inc.,Tarrytown, New York., Leal S; Bayer Consumer Care AG,Basel, Switzerland., Amer F; Regeneron Pharmaceuticals, Inc.,Tarrytown, New York., Moini H; Regeneron Pharmaceuticals, Inc.,Tarrytown, New York., Bussfeld P; Bayer Consumer Care AG,Basel, Switzerland., Vitti R; Regeneron Pharmaceuticals, Inc.,Tarrytown, New York.

المصدر: Retina (Philadelphia, Pa.) [Retina] 2021 Apr 01; Vol. 41 (4), pp. 669-670.

نوع المنشور: Editorial

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8309919 Publication Model: Print Cited Medium: Internet ISSN: 1539-2864 (Electronic) Linking ISSN: 0275004X NLM ISO Abbreviation: Retina Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors/*adverse effects , Antibodies, Monoclonal, Humanized/*adverse effects , Choroidal Neovascularization/*drug therapy , Endophthalmitis/*chemically induced , Retinal Artery Occlusion/*chemically induced , Retinal Vasculitis/*chemically induced , Wet Macular Degeneration/*drug therapy, Endophthalmitis/diagnosis ; Humans ; Intravitreal Injections ; Receptors, Vascular Endothelial Growth Factor/therapeutic use ; Recombinant Fusion Proteins/adverse effects ; Recombinant Fusion Proteins/therapeutic use ; Retinal Artery Occlusion/diagnosis ; Retinal Vasculitis/diagnosis ; Risk Factors

المؤلفون: Heier JS; Ophthalmic Consultants of Boston, Boston, Massachusetts., Wykoff CC; Retina Consultants of Houston, Houston, Texas., Waheed NK; New England Eye Center, Boston, Massachusetts., Kitchens JW; Retina Associates of Kentucky, Lexington, Kentucky., Patel SS; Retina Research Institute of Texas, Abilene, Texas., Vitti R; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Perlee L; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Chu KW; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Leal S; Bayer Healthcare, Berlin, Germany., Asmus F; Bayer Healthcare, Berlin, Germany., Son V; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Schmelter T; Bayer Healthcare, Berlin, Germany., Brown DM; Retina Consultants of Houston, Houston, Texas. Electronic address: dmbmd@houstonretina.com.

المصدر: Ophthalmology [Ophthalmology] 2020 Feb; Vol. 127 (2), pp. 211-220. Date of Electronic Publication: 2019 Sep 25.

نوع المنشور: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-4713 (Electronic) Linking ISSN: 01616420 NLM ISO Abbreviation: Ophthalmology Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors/*therapeutic use , Choroidal Neovascularization/*drug therapy , Receptor, Platelet-Derived Growth Factor beta/*antagonists & inhibitors , Receptors, Vascular Endothelial Growth Factor/*therapeutic use , Recombinant Fusion Proteins/*therapeutic use , Wet Macular Degeneration/*drug therapy, Aged ; Aged, 80 and over ; Choroidal Neovascularization/diagnosis ; Choroidal Neovascularization/physiopathology ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Intravitreal Injections ; Male ; Treatment Outcome ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity/physiology ; Wet Macular Degeneration/diagnosis ; Wet Macular Degeneration/physiopathology

المؤلفون: Khurana RN; Northern California Retina Vitreous Associates, Mountain View, California, USA., Rahimy E; Palo Alto Medical Foundation, Palo Alto, California, USA., Joseph WA; Ophthalmic Consultants of Boston, Boston, Massachusetts, USA., Saroj N; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA., Gibson A; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA., Vitti R; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA., Berliner AJ; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA., Chu K; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA., Cheng Y; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA., Boyer DS; Retina-Vitreous Associates Medical Group, Beverly Hills, California, USA. Electronic address: vitdoc@aol.com.

المصدر: American journal of ophthalmology [Am J Ophthalmol] 2019 Apr; Vol. 200, pp. 161-168. Date of Electronic Publication: 2019 Jan 19.

نوع المنشور: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Country of Publication: United States NLM ID: 0370500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1891 (Electronic) Linking ISSN: 00029394 NLM ISO Abbreviation: Am J Ophthalmol Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors/*administration & dosage , Choroidal Neovascularization/*drug therapy , Ranibizumab/*administration & dosage , Receptors, Vascular Endothelial Growth Factor/*administration & dosage , Recombinant Fusion Proteins/*administration & dosage , Wet Macular Degeneration/*drug therapy, Aged ; Aged, 80 and over ; Choroidal Neovascularization/diagnosis ; Choroidal Neovascularization/physiopathology ; Double-Blind Method ; Female ; Fluorescein Angiography ; Humans ; Intravitreal Injections ; Male ; Middle Aged ; Time Factors ; Tomography, Optical Coherence ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity/physiology ; Wet Macular Degeneration/diagnosis ; Wet Macular Degeneration/physiopathology

المؤلفون: Jaffe GJ; Department of Ophthalmology, Duke University, Durham, North Carolina. Electronic address: glenn.jaffe@duke.edu., Kaiser PK; Cole Eye Institute, Cleveland, Ohio., Thompson D; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Gibson A; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Saroj N; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Vitti R; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Berliner AJ; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Heier JS; Ophthalmic Consultants of Boston, Boston, Massachusetts.

المصدر: Ophthalmology [Ophthalmology] 2016 Sep; Vol. 123 (9), pp. 1856-64. Date of Electronic Publication: 2016 Jun 28.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-4713 (Electronic) Linking ISSN: 01616420 NLM ISO Abbreviation: Ophthalmology Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors/*therapeutic use , Choroidal Neovascularization/*drug therapy , Ranibizumab/*therapeutic use , Receptors, Vascular Endothelial Growth Factor/*therapeutic use , Recombinant Fusion Proteins/*therapeutic use , Wet Macular Degeneration/*drug therapy, Aged ; Female ; Fluorescein Angiography ; Humans ; Intravitreal Injections ; Male ; Middle Aged ; Retina/pathology ; Subretinal Fluid/metabolism ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity/physiology ; Wet Macular Degeneration/pathology ; Wet Macular Degeneration/physiopathology

المؤلفون: Ikuno Y; Osaka University Medical School, Osaka, Japan. Electronic address: yasushi.ikuno@gmail.com., Ohno-Matsui K; Osaka University Medical School, Osaka, Japan., Wong TY; Osaka University Medical School, Osaka, Japan., Korobelnik JF; Osaka University Medical School, Osaka, Japan., Vitti R; Osaka University Medical School, Osaka, Japan., Li T; Osaka University Medical School, Osaka, Japan., Stemper B; Osaka University Medical School, Osaka, Japan., Asmus F; Osaka University Medical School, Osaka, Japan., Zeitz O; Osaka University Medical School, Osaka, Japan., Ishibashi T; Osaka University Medical School, Osaka, Japan.

المصدر: Ophthalmology [Ophthalmology] 2016 Feb; Vol. 123 (2), pp. e17-e18.

نوع المنشور: Letter; Comment

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print Cited Medium: Internet ISSN: 1549-4713 (Electronic) Linking ISSN: 01616420 NLM ISO Abbreviation: Ophthalmology Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors/*therapeutic use , Choroidal Neovascularization/*drug therapy , Myopia, Degenerative/*drug therapy , Receptors, Vascular Endothelial Growth Factor/*therapeutic use , Recombinant Fusion Proteins/*therapeutic use, Female ; Humans ; Male

المؤلفون: Ikuno Y; Department of Ophthalmology, Osaka University School of Medicine, Osaka, Japan., Ohno-Matsui K; Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan., Wong TY; Singapore Eye Research Institute, Singapore National Eye Center, Duke-NUS Graduate Medical School, National University of Singapore, Singapore., Korobelnik JF; Service d'ophtalmologie, Hopital Pellegrin-CHU de Bordeaux, Bordeaux, France; Université Bordeaux Segalen, Bordeaux, France; INSERM, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France., Vitti R; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Li T; Bayer HealthCare Pharmaceuticals, Beijing, China., Stemper B; Bayer HealthCare Pharmaceuticals, Berlin, Germany; Department of Neurology, University of Erlangen-Nürnberg, Erlangen, Germany., Asmus F; Bayer HealthCare Pharmaceuticals, Berlin, Germany; Department of Neurodegeneration, Center of Neurology, University Hospital of Tübingen, and Hertie Institute for Clinical Brain Research, Tübingen, Germany., Zeitz O; Bayer HealthCare Pharmaceuticals, Berlin, Germany; Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany., Ishibashi T; Department of Ophthalmology, Kyushu University, Fukuoka, Japan. Electronic address: ishi@eye.med.kyushu-u.ac.jp.

مؤلفون مشاركون: MYRROR Investigators

المصدر: Ophthalmology [Ophthalmology] 2015 Jun; Vol. 122 (6), pp. 1220-7. Date of Electronic Publication: 2015 Mar 04.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-4713 (Electronic) Linking ISSN: 01616420 NLM ISO Abbreviation: Ophthalmology Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors/*therapeutic use , Choroidal Neovascularization/*drug therapy , Myopia, Degenerative/*drug therapy , Receptors, Vascular Endothelial Growth Factor/*therapeutic use , Recombinant Fusion Proteins/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Choroidal Neovascularization/etiology ; Choroidal Neovascularization/physiopathology ; Double-Blind Method ; Female ; Humans ; Intravitreal Injections ; Male ; Middle Aged ; Myopia, Degenerative/complications ; Myopia, Degenerative/physiopathology ; Tomography, Optical Coherence ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity/physiology

المؤلفون: Nguyen QD; Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9277, USA. qnguyen4@jhmi.edu, Campochiaro PA, Shah SM, Browning DJ, Hudson HL, Sonkin PL, Hariprasad SM, Kaiser PK, Slakter J, Haller JA, Do DV, Mieler W, Chu K, Ingerman A, Vitti R, Berliner AJ, Cedarbaum J

مؤلفون مشاركون: Clear-It 1 Investigators

المصدر: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics [J Ocul Pharmacol Ther] 2012 Dec; Vol. 28 (6), pp. 581-8. Date of Electronic Publication: 2012 Jul 09.

نوع المنشور: Clinical Trial, Phase I; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Association For Ocular Pharmacology And Therapeutics Country of Publication: United States NLM ID: 9511091 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-7732 (Electronic) Linking ISSN: 10807683 NLM ISO Abbreviation: J Ocul Pharmacol Ther Subsets: MEDLINE

مواضيع طبية MeSH: Choroidal Neovascularization/*drug therapy , Macular Degeneration/*drug therapy , Receptors, Vascular Endothelial Growth Factor/*therapeutic use , Recombinant Fusion Proteins/*therapeutic use , Visual Acuity/*drug effects, Aged ; Aged, 80 and over ; Choroidal Neovascularization/pathology ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Fovea Centralis/drug effects ; Fovea Centralis/pathology ; Humans ; Intravitreal Injections ; Macular Degeneration/pathology ; Male ; Middle Aged ; Prospective Studies ; Receptors, Vascular Endothelial Growth Factor/administration & dosage ; Receptors, Vascular Endothelial Growth Factor/adverse effects ; Recombinant Fusion Proteins/administration & dosage ; Recombinant Fusion Proteins/adverse effects ; Treatment Outcome

المؤلفون: Brown DM; Retina Consultants of Houston, The Methodist Hospital, Houston, Texas, USA. dmbmd@houstonretina.com, Heier JS, Ciulla T, Benz M, Abraham P, Yancopoulos G, Stahl N, Ingerman A, Vitti R, Berliner AJ, Yang K, Nguyen QD

مؤلفون مشاركون: CLEAR-IT 2 Investigators

المصدر: Ophthalmology [Ophthalmology] 2011 Jun; Vol. 118 (6), pp. 1089-97.

نوع المنشور: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print Cited Medium: Internet ISSN: 1549-4713 (Electronic) Linking ISSN: 01616420 NLM ISO Abbreviation: Ophthalmology Subsets: MEDLINE

مواضيع طبية MeSH: Choroidal Neovascularization/*prevention & control , Fovea Centralis/*pathology , Vascular Endothelial Growth Factor A/*administration & dosage , Wet Macular Degeneration/*drug therapy, Aged ; Aged, 80 and over ; Choroidal Neovascularization/diagnosis ; Choroidal Neovascularization/etiology ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Fovea Centralis/drug effects ; Humans ; Intravitreal Injections ; Male ; Middle Aged ; Prospective Studies ; Treatment Outcome ; Vascular Endothelial Growth Factor A/therapeutic use ; Visual Acuity ; Wet Macular Degeneration/complications ; Wet Macular Degeneration/diagnosis

المؤلفون: Heier JS; Ophthalmic Consultants of Boston, Boston, Massachusetts, USA., Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, Stahl N, Ingerman A, Vitti R, Berliner AJ, Yang K, Brown DM

مؤلفون مشاركون: CLEAR-IT 2 Investigators

المصدر: Ophthalmology [Ophthalmology] 2011 Jun; Vol. 118 (6), pp. 1098-106.

نوع المنشور: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print Cited Medium: Internet ISSN: 1549-4713 (Electronic) Linking ISSN: 01616420 NLM ISO Abbreviation: Ophthalmology Subsets: MEDLINE

مواضيع طبية MeSH: Choroidal Neovascularization/*drug therapy , Fovea Centralis/*pathology , Vascular Endothelial Growth Factor A/*administration & dosage , Wet Macular Degeneration/*complications, Aged ; Aged, 80 and over ; Choroidal Neovascularization/etiology ; Choroidal Neovascularization/pathology ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Fovea Centralis/drug effects ; Humans ; Intravitreal Injections ; Male ; Middle Aged ; Ophthalmoscopy ; Prospective Studies ; Time Factors ; Treatment Outcome ; United States ; Vascular Endothelial Growth Factor A/therapeutic use ; Visual Acuity ; Wet Macular Degeneration/drug therapy ; Wet Macular Degeneration/pathology

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.